Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib® treatment

Acta Ophthalmologica

Volumn 86, Issue 4, 2008, Pages 456-458

  Kernt, Marcus ^a   Staehler, Michael ^b   Stief, Christian ^b   Kampik, Anselm ^a   Neubauer, Aljoscha S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Age related macular degeneration (AMD); Protein kinase inhibitor; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; BIOMICROSCOPY; CASE REPORT; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; KIDNEY CANCER; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETINA MACULA EDEMA;

ADMINISTRATION, ORAL; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR EDEMA; MALE; PYRIDINES;

EID: 47649105756     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01014.x     Document Type: Article

References (11)

1. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM & Santoro M (2006): BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334.
2. Escudier B, Eisen T, Stadler WM et al. (2007): Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
3. Kvanta A, Algvere PV, Berglin L & Seregard S (1996): Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934.
4. Lu M & Adamis AP (2006): Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 19: 323-334.
5. Ratain MJ, Eisen T, Stadler WM et al. (2006): Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512.
6. Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511.
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY & Kim RY (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
8. Schlingemann RO (2004): Role of growth factors and the wound-healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242: 91-101.
9. Spaide RF, Laud K, Fine HF, Klancnik JM Jr et al. (2006): Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390.
10. Wilhelm SM, Carter C, Tang L et al. (2004): BAY 43-9006 exhibits broad spectrum oral anti-tumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 64: 7099-7109.
11. Williams AJ & Fekrat S (2006): Progression of choroidal neovascularization following injection of pegaptanib sodium (Macugen) in two eyes with neovascular age-related macular degeneration. Am J Ophthalmol 142: 683-684.